Problem-Solving Therapy for Cancer Caregivers in Outpatient Palliative Care

NAEnrolling by invitationINTERVENTIONAL
Enrollment

570

Participants

Timeline

Start Date

January 24, 2022

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Depression, AnxietyPalliative CareCaregiversCancer
Interventions
BEHAVIORAL

Problem-Solving Therapy

Over an approximately 3-week period, family caregivers randomized to the intervention study arm will learn and apply a problem-solving approach based on the ADAPT model, which encourages participants to follow five steps when solving caregiving problems: 1) focus on adopting a positive attitude to problem solving, 2) define the problem and set goals, 3) generate a list of alternative solutions to the problem, 4) predict consequences of the alternative solutions, and 5) try implementing the most promising solution from among the list of alternatives. The intervention will be delivered by a trained interventionist over the course of three structured sessions via telephone or videoconferencing technology, depending on the FCG's preference. Session content will be summarized in an intervention manual, which we will provide to all intervention participants. Sessions will last approximately 45-60 minutes.

OTHER

Attention-matched Control

"Over an approximately 3-week period, family caregivers randomized to the attention control study arm will participate in informal conversations (friendly visits) with a trained member of the research team."

OTHER

In-depth interviews

The 30 key stakeholders interviews will discuss how the PST intervention fits into existing clinical practice and institutional values, what might incentivize adoption of the PST intervention, and how the intervention compares to alternative existing or proposed programs.

Trial Locations (3)

19104

University of Pennslyvania, Philadelphia

63110

Washington University School of Medicine, St Louis

65211

University of Missouri, Columbia

All Listed Sponsors
collaborator

University of Pennsylvania

OTHER

collaborator

National Cancer Institute (NCI)

NIH

collaborator

University of Missouri-Columbia

OTHER

lead

Washington University School of Medicine

OTHER